US Pat. No. 11,028,452

ASSAY FOR THE DIAGNOSIS OF DERMATOPHYTOSIS

EUROIMMUN Medizinische La...

1. A primer pair, comprising:a forward primer having a length of 14 to 30 nucleotides, being at least 90% identical to Trichophyton sequence over the full-length of the forward primer, and having a final base of the forward primer no more than 200 bp away from a first base of SEQ ID NO: 1 in a 5? to 3? orientation, and
a reverse primer having a length of 14 to 30 nucleotides, being at least 90% identical to Trichophyton sequence over the full-length of the reverse primer, and having a final base of the reverse primer is no more than 200 bp away from a final base of SEQ ID NO: 1 in the 5? to 3? orientation,
wherein each of the forward primer and the reverse primer are labeled with a label and form the primer pair, wherein the label is selected from the group consisting of a fluorescent label, a radioactive label, a colloidal gold label, and an enzymatically active label,
wherein the forward primer and reverse primer, in combination, amplify a nucleic acid comprising a sequence having at least 98% identity to the full-length of SEQ ID NO: 1 from a human pathogenic dermatophyte that causes at least one of a skin, hair, and nail infection, the human pathogenic dermatophyte belonging to a Trichophyton genus.
US Pat. No. 11,028,197

PROCESSES TO PRODUCE POLY ALPHA-OLEFIN TRIMER AND APPARATUS THEREFOR

ExxonMobil Chemical Paten...

1. A process to produce a poly alpha-olefin (PAO), comprising:a) introducing a first alpha-olefin to a first catalyst system comprising activator and a metallocene compound into a continuous stirred tank reactor or a continuous tubular reactor under first reactor conditions, wherein the first alpha-olefin is introduced to the reactor at a flow rate of about 100 g/hr or more, to form a first reactor effluent comprising at least 60 wt % of PAO dimer and 40 wt % or less of higher oligomers, where the higher oligomers are oligomers that have a degree of polymerization of 3 or more; and
b) introducing the first reactor effluent and a second alpha-olefin to a second catalyst composition comprising an acid catalyst in a second reactor to form a second reactor effluent comprising PAO trimer,
wherein the higher oligomers in the first reactor effluent are not separated from the first effluent stream prior to introduction into the second reactor.
US Pat. No. 11,028,453

QTLS ASSOCIATED WITH AND METHODS FOR IDENTIFYING LODGING RESISTANCE IN SOYBEAN

PIONEER HI-BRED INTERNATI...

1. A method of selecting a first soybean plant or soybean germplasm that displays improved lodging resistance, the method comprising:(a) detecting in a first soybean plant or soybean germplasm at least one allele of one or more marker locus within or linked to a quantitative trait locus (QTL) associated with improved lodging resistance, wherein the allele positively correlates with improved lodging resistance, and wherein the at least one allele of the one or more marker locus comprises an allele selected from the group consisting of allele A of marker locus Gm13:36431456, allele T of marker locus Gm13:36490271, allele T of marker locus Gm13:36491753, allele T of marker locus Gm13:36491754, allele T of marker locus Gm13:36492037, allele G of marker locus Gm13:36492926, allele A of marker locus Gm13:36492955, allele G of marker locus Gm13:36493615, allele G of marker locus Gm13:36494839, allele A of marker locus Gm13:36517239, allele T of marker locus Gm13:36539789, allele T of marker locus Gm13:36539798, allele C of marker locus Gm13:36540415, allele C of marker locus Gm13:36593549, allele T of marker locus Gm13:36613902, allele T of marker locus Gm13:36644196, allele T of marker locus Gm13:36644203, allele T of marker locus Gm13:36644207, allele A of marker locus Gm13:36678427, allele G of marker locus Gm13:36697528, allele T of marker locus Gm13:36795108, allele C of marker locus Gm13:36704369, allele A of marker locus Gm13:36300296, allele T of marker locus Gm13:36567042, allele A of marker locus Gm13:36792347, allele A of marker locus Gm13:36864280, and allele G of marker locus Gm13:37443784;
(b) selecting a first soybean plant or soybean germplasm comprising the at least one allele from step (a), thereby selecting a soybean plant or soybean germplasm that displays improved lodging resistance; and
(c) crossing the selected first soybean plant or soybean germplasm with a second soybean plant or soybean germplasm to introgress the QTL into a progeny soybean plant or soybean germplasm.
US Pat. No. 11,026,918

METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION

THE BOARD OF TRUSTEES OF ...

1. A method of treating a pulmonary disease or condition in a subject comprising administering to a subject in need of treatment an effective amount of a SphK1 inhibitor to treat the subject's pulmonary disease or condition, wherein the SphK1 inhibitor(a) exhibits at least a 20-fold greater selectivity for SphK1than SphK2; and
(b) is cell permeable, has an IC50 value of less than 10 ?M, or has a Ki of less than 10 ?M, or a combination thereof.
US Pat. No. 11,028,454

INCORPORATION OF THERMO-RESISTANT AND/OR PRESSURE-RESISTANT ORGANISMS IN MATERIALS

Resilux, Wetteren (BE)

1. An apparatus comprising a beverage bottle or food container made of a material comprising a polymer and a micro-organism powder comprising living or viable spores of a micro-organism incorporated into said polymer and prepared by a process comprising mixing a polymer matrix comprising said polymer and said micro-organism powder at a pressure ranging from 1.5 to 50 bar or at temperatures ranging from 100° C. to 220° C. at a pressure ranging from 1.5 to 50 bar, wherein said micro-organism is a Bacillus amyloliquefaciens strain deposited under No. 1D9698 at the Belgian Co-ordinated Collections of Micro-organisms (BCCM), or a Bacillus strain with a gyrA sequence that is at least 95% identical to SEQ ID NO:1, and which is capable of withstanding a pressure ranging from 1.5 to 50 bar or at temperatures ranging from 100° C. to 220° C. at a pressure ranging from 1.5 to 50 bar, and wherein said polymer comprises at least one monomer selected from the group consisting of acrylates, methacrylates, acrylamides, methacrylamides, alcohols, amines, anhydrides, epoxides, styrenes, functionalized vinyls, functionalized allyls, propenes, butadienes, ethylenes, isocyanates, lactams, lactones, saccharides, glucose and esters.
US Pat. No. 11,026,407

MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE

Regeneran Pharmaceuticals...

1. A method for generating a human immunoglobulin heavy or light chain variable region sequence comprising the steps of:(a) immunizing a genetically modified mouse with an antigen of interest, wherein the genetically modified mouse comprises in its germline genome:
(i) exactly two unrearranged human immunoglobulin V? gene segments and five unrearranged human immunoglobulin J? fix gene segments operably linked to a mouse immunoglobulin light chain constant region sequence at the endogenous kappa light chain loci of the mouse, wherein the two unrearranged human immunoglobulin V? gene segments are a human V?1-39 gene segment and a human V?3-20 gene segment; and
(ii) one or more unrearranged human immunoglobulin VH gene segments, one or more unrearranged human immunoglobulin DH gene segments, and one or more unrearranged human immunoglobulin JH gene segments operably linked to a mouse immunoglobulin heavy chain constant region sequence at the endogenous heavy chain loci of the mouse;
wherein the unrearranged human immunoglobulin heavy chain and kappa light chain gene segments of the genetically modified mouse are capable of rearranging and encoding human immunoglobulin variable domains of an antibody, wherein the genetically modified mouse does not comprise endogenous immunoglobulin V? or J? gene segments that are capable of rearranging to form an immunoglobulin light chain variable region sequence; and
(b) determining a human immunoglobulin heavy or light chain variable region sequence that encodes a human heavy or kappa light chain variable domain of an antibody, respectively, that specifically binds the antigen and that was generated by the genetically modified mouse.
US Pat. No. 11,028,199

FLUOROPOLYMER POWDER AND METHOD FOR PRODUCING SAME

DAIKIN INDUSTRIES, LTD., ...

1. A powder comprising a fluoropolymer and having an aspect ratio of 3 or lower,the fluoropolymer containing at least one group A selected from the group consisting of —SO2Y, —COOR, —SO3X, —SO2NR12, and —COOX,
wherein Y is a halogen atom; R is a C1-C4 alkyl group; X is M1/L or NR14, where M is a hydrogen atom or an L-valent metal, the L-valent metal being a metal in group 1, group 2, group 4, group 8, group 11, group 12, or group 13 of the periodic table; and R1s are each individually a hydrogen atom or a C1-C4 alkyl group,
the powder exhibiting a dispersion of 50% or higher, the dispersion being calculated by filtering a composition obtained by mixing the powder with water through a mesh having an opening of 20 ?m,
wherein the powder has an average primary particle size of greater than 30 nm to 300 nm.
US Pat. No. 11,026,408

GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF

Regeneron Pharmaceuticals...

1. A method for in vivo evaluation of a vaccine, the method comprising:administering a vaccine to a genetically modified mouse, wherein the genetically modified mouse comprises in its genome:
a recombination activating gene 2 (Rag-2) gene knock-out,
an IL2 receptor gamma chain (IL2rg) gene knock-out,
a replacement of a mouse M-CSF gene with a nucleic acid encoding a human M-CSF polypeptide at a mouse M-CSF gene locus,
a replacement of a mouse IL-3 gene with a nucleic acid encoding a human IL-3 polypeptide at a mouse IL-3 gene locus,
a replacement of a mouse GM-CSF gene with a nucleic acid encoding a human GM-CSF polypeptide at a mouse GM-CSF gene locus,
a replacement of a mouse TPO gene with a nucleic acid encoding a human TPO polypeptide at a mouse TPO gene locus, and
an insertion of a nucleic acid encoding a human SIRP polypeptide,
wherein each of the nucleic acids encoding the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRP polypeptide, and the human TPO polypeptide is operably linked to a promoter,
wherein the mouse expresses the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRPA polypeptide, and the human TPO polypeptide, and
wherein the mouse is engrafted with human hematopoietic cells; and
assessing an immune response to the vaccine in the genetically modified mouse.
US Pat. No. 11,026,920

USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS

VYNE THERAPEUTICS INC., ...

20. A method of administering a therapeutically effective amount of 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one (serlopitant) or a pharmaceutically acceptable salt, solvate or polymorph thereof and a corticosteroid to a patient with a viral infection in need of treatment;wherein serlopitant is administered one, two, three or more times per day, orally, by injection or infusion and the corticosteroid is administered one, two, three or more times per day, intranasally, pulmonarily, by injection or infusion;
wherein at least one loading dose of serlopitant is administered, and at least one therapeutically effective maintenance dose of serlopitant is subsequently administered, wherein the at least one loading dose is five times, four times, three times or two times larger than the at least one therapeutically effective maintenance dose or the at least one loading dose is 0.75 mg, 3 mg, or 15 mg, and the at least one therapeutically effective maintenance dose is 0.25 mg, 1 mg, or 5 mg;
wherein about 0.1 mg to about 30 mg, or from about 1 mg to about 7.5 mg of serlopitant is administered daily; and
wherein the corticosteroid is administered concurrently with or sequentially (before or after) administration of serlopitant.
US Pat. No. 11,026,409

PHYTOSEIID PREDATORY MITE RELEASING SYSTEM AND METHOD FOR PRODUCTION

Koppert B.V., Berkel en ...

1. A composition for releasing Phytoseiid predatory mites, the composition comprising:a population of the Phytoseiid predatory mite, wherein the Phytoseiid predatory mite is selected from Amblyseius swirskii, and Neoseiulus cucumeris;
a food source for the individuals of the Phytoseiid predatory mite population, comprising:
a population of a first factitious host mite that is a factitious host for the Phytoseiid predatory mite, wherein the first factitious host is Lepidoglyphus destructor; and
a population of a second factitious host mite that is a factitious host for the Phytoseiid predatory mite, wherein the second factitious host is Carpoglyphus lactis; and
a carrier comprising a food source for the host mites.
US Pat. No. 11,026,921

COMPOSITIONS AND METHODS OF TREATING CANCER

Dana-Farber Cancer Instit...

1. A method of treating a tumor in a patient comprising administering to said patient a composition comprising a population of autologous dendritic cell/tumor cell fusions (DC/tumor fusions) and an immunomodulatory agent, wherein the immunomodulatory agent is pomalidomide and/or apremilast.
US Pat. No. 11,028,201

POLYMER COMPOSITION

LG Chem, Ltd.

1. A polymer composition, comprising:a first block copolymer having a polymer segment A and a polymer segment B; and
a second block copolymer having a polymer segment C and a polymer segment D,
wherein the second block copolymer having a number average molecular weight (M2) lower than a number average molecular weight (M1) of the first block copolymer,
wherein the polymer segments A and C each comprise a side chain having 8 or more chain-forming atoms.
US Pat. No. 11,026,922

COMPOSITIONS COMPRISING MELATONIN AND FLAVONOIDS FOR USE IN THE TREATMENT OF TUMOURS RESISTANT TO CHEMOTHERAPY

PROBIOTICAL S.P.A., Nova...

1. A method for treatment of chemoresistant tumours in an individual, the method comprising:administering to the individual a mixture comprising in effective amounts therefor:
(i) rutin at a concentration of at least 20 ?M; and
(ii) melatonin at a concentration of at least 0.1 mM,
wherein the chemoresistant tumour is breast cancer in woman.
US Pat. No. 11,028,458

STEEL SHEET AND PLATED STEEL SHEET

NIPPON STEEL CORPORATION,...

1. A steel sheet comprisinga chemical composition consisting of, in mass percent:
C: 0.01 to 0.20%;
Si: 0.005 to 0.10%;
Mn: 0.60 to 4.00%;
Al: 0.55 to 3.00%;
P: 0.10% or less;
S: 0.03% or less;
N: 0.01% or less;
O: 0.01% or less;
Ti: 0 to 2.00%;
Nb: 0 to 2.00%;
V: 0 to 0.30%;
Cu: 0 to 2.00%;
Ni: 0 to 2.00%;
Mo: 0 to 1.00%;
Cr: 0 to 2.00%;
B: 0 to 0.01%;
Ca: 0 to 0.010%;
Mg: 0 to 0.010%;
Zr: 0 to 0.050%;
REM: 0 to 0.1%;
Sb: 0 to 0.10%;
Sn: 0 to 0.10%; and
As: 0 to 0.5%,
with the balance: Fe and impurities, and comprising
a microstructure that includes,
when a zone surrounded by a grain boundary that is measured to be 5.0° or more by an EBSD analysis is assumed to be a grain, and when
a K value is a value obtained by multiplying an average value of Image Qualities in a grain by 10?3,
a Y value is an average crystal misorientation (°) in the grain,
a metallic phase 1 is a metallic phase the K value of which is less than 4.000,
a metallic phase 2 is a metallic phase the K value of which is 4.000 or more and the Y value of which is 0.5 to 1.0,
a metallic phase 3 is a metallic phase the K value of which is 4.000 or more and the Y value of which is less than 0.5, and
a metallic phase 4 is a metallic phase that falls under none of metallic phases 1 to 3, and the metallic phase 4 comprises at least one of upper bainite, lower bainite, in area percent:
the metallic phase 1: 1.0% or more and less than 35.0%;
the metallic phase 2: 30.0% or more and 80.0% or less;
the metallic phase 3: 5.0% or more and 50.0% or less; and
the metallic phase 4: 5.0% or less.
US Pat. No. 11,028,203

MOLECULAR IMPRINTED POLYMERS TARGETING PHENYLALANINE

Mipsalus APS, Horsholm (...

1. A method for the preparation of molecular imprinted polymers (MIPs), which specifically bind L-phenylalanine (Phe) and L-Phe residues, said method comprising the steps ofa) polymerization of a mixture comprising
2-methylprop-2-enoic acid (MAA),
1,4-bis(acryloyl)piperazine (DAP), and
a template molecule consisting of L-Phe or a L-Phe derivative exposing a phenylalanine motif in the presence of a catalyst and an oxidizing agent,
so as to obtain a cross-linked imprinted polymer,
b) if necessary subsequently fragmenting the cross-linked imprinted polymer to obtain a first fragmented polymer, and collecting the MIPs having particle sizes smaller than 63 ?m,
c) optionally washing and drying the polymer fraction obtained from step b),
d) fragmenting the polymer fraction obtained from step b) or c) and collecting a second fragmented polymer having particle sizes in the range 150-250 nm,
e) subjecting the second fragmented polymer obtained from step d to affinity chromatography where Phe constitutes the affinity tag in a chromatographic matrix, and
f) recovering MIPs binding to Phe in step e).
US Pat. No. 11,028,204

CURABLE COMPOSITIONS COMPRISING MONO-FUNCTIONAL ACRYLATES

Arkema France, Colombes ...

1. A curable composition comprising:a) at least one (meth)acrylate or oligomer selected from the group consisting of monofunctional oligomeric (meth)acrylates, multifunctional oligomeric (meth)acrylates, and combinations thereof;
b) at least one mono-functional (meth)acrylate monomer comprising tricyclodecane methanol monoacrylate having three rings that are fused or condensed; and
wherein a) and b) are different.
US Pat. No. 11,026,925

ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR COMPOSITE AND PREPARATION METHOD THEREOF

SHENZHEN SALUBRIS PHARMAC...

1. A supramolecular complex of angiotensin II receptor metabolite and NEP inhibitor, wherein the formula unit of the supramolecular complex is:(aEXP3174.bAHU377).xCa.nA,
wherein the molar ratio of a to b is from 1:0.25 to 1:4, x is from 0.5 to 3, A is water, methanol, ethanol, 2-propyl alcohol, acetone, ethyl acetate, methyl-tert-butyl ether, acetonitrile, methylbenzene or dichloromethane, and n is from 0 to 3.
US Pat. No. 11,028,461

BAUXITE RESIDUE RECYCLING

Worcester Polytechnic Ins...

1. A method for recovering scandium from mined red mud, comprising:adding an acid to a quantity of red mud for converting oxides in the red mud;
roasting the quantity of red mud;
adding water to the roasted red mud for leaching the converted oxides into a leach liquor mixture including scandium and rare earths;
agitating the leach liquor mixture to increase an exposed surface area of red mud particles in the leach liquor;
adjusting the pH of the leach liquor to precipitate the rare earths while leaving the scandium in solution in the leach liquor;
precipitating scandium oxalate from the leach liquor by reducing the pH and adding oxalic acid; and
filtering the precipitated scandium oxalate from the leach liquor.
US Pat. No. 11,028,206

POLYMERIZABLE COMPOSITION FOR OPTICAL ARTICLES

PPG Industries Ohio, Inc....

1. A polymerizable composition, comprising the reaction product of:an isohexide bischloroformate;
at least one polyol comprising a linear or branched polyol;
allyl alcohol; and
optionally, at least one polychloroformate.
US Pat. No. 11,026,927

PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST

ACTELION PHARMACEUTICALS ...

1. A pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof, wherein the first agent and the second agent are in synergistically effective amounts for the treatment of multiple sclerosis.
US Pat. No. 11,028,207

FLAME RETARDANT POLYOLEFIN-TYPE RESIN AND PREPARATION METHOD AS WELL AS OPTIC FIBER CABLE USING THE SAME

CORNING INCORPORATED, Co...

1. A method of preparing a flame retardant grafted polyolefin resin, the method comprising the steps of:reacting in an extrusion barrel a reactive polyolefin and a monomeric flame retardant agent to form the flame retardant grafted polyolefin resin, wherein the reactive polyolefin has a functional group including a moiety selected from the group consisting of anhydrides, epoxies, carboxylic acids, ketones, and isocyanates and wherein the monomeric flame retardant agent has an amine functional group and contains at least one element selected from the group consisting of phosphorus, nitrogen, silicon, and sulfur, the at least one element comprising more than 10% by weight of the monomeric flame retardant agent; and
extruding the flame retardant grafted polyolefin resin.
US Pat. No. 11,028,208

TERMINAL-FUNCTIONALIZED POLYMER, RUBBER COMPOSITION CONTAINING SAME AND RELATED PROCESSES

Bridgestone Corporation, ...

1. A terminal-functionalized polymer having a structure according to formula I(P)nSi(R)k(OR)m—SP—U  (I)
wherein P is a polymer chain comprising at least one type of conjugated diene monomer and optionally at least one type of vinyl aromatic monomer,
n is an integer of 1-3, m is an integer of 0-2, k is an integer of 0 or 1, m+n+k=3,
each R is independently selected from: (i) an alkyl group having 1 to 20 carbons, (ii) a cycloalkyl group having 3 to 20 carbons, (iii) an aryl group having 6 to 20 carbons, (iv) an alkylaryl group having 7 to 20 carbons, or (v) SiR1R2R3 where each of R1, R2
and R3 is independently selected from H, (i), (ii), (iii), or (iv)
SP is a spacer group having at least two carbon atoms and is optionally substituted with at least one heteroatom selected from S, O, or NR, and
U is a moiety containing at least two carbon-carbon double bonds in a conjugated configuration.
US Pat. No. 11,026,929

ADMINISTRATION OF BERBERINE METABOLITES

Keto Patent Group, Inc., ...

1. A method of managing glucose tolerance in an individual, the method comprising:administering, to an individual a pharmaceutically effective amount of R-beta-hydroxybutyrate, wherein the pharmaceutically effective amount of R-beta-hydroxybutyrate comprises less than approximately 2 g of R-beta-hydroxybutyrate.
US Pat. No. 11,028,465

LOW-COST LEAD-FREE DEZINCIFICATION-RESISTANT BRASS ALLOY FOR CASTING

Xiamen Lota International...

1. A dezincification-resistant brass alloy, wherein the brass alloy consists of 60-65 wt. % of Cu, 0.05-0.25 wt. % of Pb, 0.53-0.8 wt. % of Al, less than 0.1 wt. % of Sn, 0.05-0.16 wt. % of As, with the balance being Zn and unavoidable impurities.
US Pat. No. 11,026,930

COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE

Shy Therapeutics LLC, Ha...

1. An assay for identifying a compound as a modulator of Ras activity, wherein the assay comprises:a) contacting a compound with a Ras protein;
b) incubating a cyanine-labeled GTP with the compound and the Ras protein; and
c) measuring the amount of the cyanine-labeled GTP bound to the Ras protein.
US Pat. No. 11,028,466

UNLEADED FREE-CUTTING BRASS ALLOYS WITH EXCELLENT CASTABILITY, METHOD FOR PRODUCING THE SAME, AND APPLICATION THEREOF

Fortune Mfg. Co., Ltd., ...

1. An unleaded free-cutting brass alloy, comprising:copper: 68 to 75 weight %,
zinc: 22.5 to <30 weight %,
silicon: 1.0 to 2.0 weight %,
at least one element selected from the group consisting of 0.01 to 0.8 weight % of nickel and 0.01 to 0.55 weight % of antimony, and
unavoidable impurities,
wherein the total content of copper and zinc in the brass alloy is 97.5 weight % or more, and
wherein the ?-phase of the brass alloy is uniformly distributed between phase boundaries of the ?-phase and the ?-phase of the brass alloy in a granular shape.
US Pat. No. 11,026,931

METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS

Neurocrine Biosciences, I...

1. A method of treating a patient with tardive dyskinesia, comprising:administering a vesicular monoamine transporter 2 (VMAT2) inhibitor chosen from (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester and pharmaceutically acceptable salts thereof to the patient, wherein the VMAT2 inhibitor is administered in an amount equivalent to about 40 mg, about 60 mg, or about 80 mg of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester free base once daily;
monitoring the patient for one or more exposure-related adverse reactions; and
discontinuing administration of the VMAT2 inhibitor based on the patient's ability to tolerate one or more exposure-related adverse reactions;
wherein the one or more exposure-related adverse reactions is selected from hypersensitivity reactions.
US Pat. No. 11,026,420

PEROXYFORMIC ACID COMPOSITIONS FOR MEMBRANE FILTRATION CLEANING IN ENERGY SERVICES

Ecolab USA Inc., Saint P...

1. A method for removing mineral deposits from a membrane system comprising:contacting a membrane fouled with mineral deposits comprising sulfate, sulfur, and/or sulfide with a peroxyformic acid composition comprising peroxyformic acid and hydrogen peroxide, wherein the ratio of the peroxyformic acid to the hydrogen peroxide in the peroxyformic acid composition is from about 5:1 to about 40:1; and
removing the mineral deposits from the membrane;
wherein the contacting occurs not more frequently than once every 24 hours, and wherein the peroxyformic acid composition contacts the membrane for less than about 12 hours; and
wherein the peroxyformic acid composition is membrane compatible and does not damage the membrane as measured by a decrease in flux of the membrane.
US Pat. No. 11,028,212

CHLOROPRENE GRAFT COPOLYMER LATEX, METHOD FOR PRODUCING SAME, BONDING AGENT AND ADHESIVE

SHOWA DENKO K.K., Tokyo ...

1. A method for producing a chloroprene graft copolymer latex, the method comprising:a chloroprene polymerization step of subjecting monomer material consisting of (i) chloroprene (A-1) or (ii) chloroprene (A-1) and a monomer (A-2) copolymerizable with chloroprene (A-1) to emulsion radical polymerization to give a chloroprene polymer, and yielding a chloroprene polymer latex in which particles of the chloroprene polymer are dispersed in water; and
a graft copolymerization step of adding, to the chloroprene polymer latex, a (meth)acrylate (B) represented by general formula: CH2?CR—CO—OR? (in the general formula, R is a methyl group or a hydrogen atom; and R? is an alkyl group having a carbon number of 4 or more and 12 or less), adding, as a polymerization initiator, an organic peroxide (C) having an octanol/water partition coefficient of ?2.0 or more and 3.0 or less to subject the chloroprene polymer to graft copolymerization with the (meth)acrylate (B) at a temperature of 10° C. or more and 40° C. or less to give a chloroprene graft copolymer, and yielding a chloroprene graft copolymer latex in which particles of the chloroprene graft copolymer are dispersed in water;
wherein the chloroprene polymer latex contains no organic solvent, and
wherein the monomer (A-2) is selected from the group consisting of 2,3-dichloro-1,3-butadiene, 1-chloro-1,3-butadiene, butadiene, isoprene, styrene, methacrylic acid, acrylic acid, itaconic acid, 2-ethylmethacrylic acid and 2-butylacrylic acid.
US Pat. No. 11,028,213

PRODUCTION OF DISPERSANTS BY NITROXIDE-MEDIATED SOLUTION POLYMERIZATION

SIKA TECHNOLOGY AG, Baar...

1. A process for preparing a copolymer, comprising polymerizing ionizable monomers m1 and side chain-bearing monomers m2 by nitroxide-mediated solution polymerization to give the copolymer, wherein the polymerization is conducted in the presence of an agent comprising a carboxyl-bearing phosphated alkoxy amine; whereinthe nitroxide-mediated solution polymerization is conducted at a pH in the range of 7.5-13, and
the monomers are converted to a copolymer having block structure, wherein the side chain-bearing monomers m2 are present in at least one first block A and ionizable monomers m1 are present in at least one second block B any proportion of monomers m1 present in the first block A is less than 15 mol % based on all the monomers m2 in the first block A, and any proportion of monomers m2 present in the second block B is less than 15 mol % based on all the monomers m1 in the second block B.
US Pat. No. 11,026,422

ACID/ANIONIC ANTIMICROBIAL AND VIRUCIDAL COMPOSITIONS AND USES THEREOF

Ecolab USA Inc., Saint P...

1. A liquid virucidal composition consisting of:from about 20 wt-% to about 40 wt-% of at least one weak acid consisting of lactic acid, citric acid, and/or malic acid;
from about 5 wt-% to about 15 wt-% of at least one strong acid consisting of methane sulfonic acid, phosphoric acid, sulfuric acid, and/or sodium bisulfate;
from about 5 wt-% to about 20 wt-% of at least one sulfonate, sulfate and/or carboxylate anionic surfactant;
water; and
optionally at least one additional functional ingredient including nonionic surfactant, solidifying agents, fragrances, and/or dyes,
wherein the composition is a liquid concentrate having an acidic pH that is non-flammable;
wherein a use pH of the composition is from about 1.5 to about 4; and
wherein the composition is a no-rinse virucidal composition effective against Norovirus.
US Pat. No. 11,028,214

SYNTHESIS OF OLIGOMER FOR OPTICAL FIBER COATING

Corning Incorporated, Co...

1. A method for making an oligomer, comprising:reacting a first precursor with a first polyol, a second polyol, and a first diol;
wherein the first precursor reacts with the first polyol to form a first urethane compound, the first polyol including two or more OH groups and a repeating alkoxylene group, the first precursor including an isocyanate group and a curable functional group; and
wherein the first precursor reacts with the second polyol to form a second urethane compound, the second polyol including two or more OH groups and a repeating alkoxylene group, wherein a molecular weight of the first polyol is greater than a molecular weight of the second polyol by at least 2500 g/mol; and
wherein the first precursor reacts with the first diol to form a third urethane compound; and
wherein a ratio of a molar amount of the first polyol to a molar amount of the first diol is greater than 10:1.
US Pat. No. 11,026,423

HERBICIDAL COMPOSITIONS AND METHODS

SePRO Corporation, Carme...

1. A method for cultivating a permanent crop plant with preemergent control of weeds in soil where a permanent crop plant resides, the permanent crop plant being a stone fruit tree, a nut tree, a pome tree, or a grape vine, the permanent crop plant having annual growing seasons that commence with a budding phase of the permanent crop, the method comprising:harvesting crop from the permanent crop plant, the crop grown during a first growing season for the permanent crop plant that occurs in a first calendar year, the harvesting step conducted during the first calendar year;
after the harvesting step and during a dormant phase of the permanent crop plant that begins in the first calendar year, applying fluridone to the soil at a rate of about 0.2 pound per acre to about 0.8 pound per acre; and
after commencement of a subsequent growing season of the permanent crop plant that follows the dormant phase, irrigating the soil, wherein the irrigating delivers an average of at least 0.1 inch of water to the soil per day over at least a 60-day period taking into account both water provided by irrigation and rainfall and ensures that the soil does not experience any period greater than one week during which the soil fails to receive at least 0.1 inch of water through irrigation or rainfall, so that the fluridone applied during the applying step is effective to provide preemergent control of weeds in the soil for said at least 60-day period during the subsequent growing season of the permanent crop plant, and
wherein the crop does not exhibit any symptoms of phytotoxicity from the fluridone as measured by chlorosis, necrosis, or other visual injury to the leaves of the plant.
US Pat. No. 11,028,215

DOPANT-FREE CONDUCTIVE BIOELASTOMERS

Board of Regents, The Uni...

20. The method of claim 19, wherein the ratio between x:y:(n+m):z is in the range of 1.8:0.2:4:1 and 1.4:0.6:4:1.
US Pat. No. 11,026,424

TEXTURIZED INSECTICIDAL FORMULATION

University of Florida Res...

1. An insecticidal composition consisting of:a texturizing agent;
an insecticide active ingredient;
a polymer, wherein the polymer is poly(isobutyl methacrylate); and
a solvent,
wherein the total amount of the insecticide active ingredient and polymer is from 1.005 weight percent to 8.1 weight percent of the composition.
US Pat. No. 11,028,216

POLYCARBODIIMIDE COPOLYMER

NISSHINBO CHEMICAL INC., ...

1. A polycarbodiimide copolymer comprising:a soft segment comprising a residue in which hydroxyl groups are removed from at least one polyol selected from the group consisting of castor oil, a castor oil-based polyol having 2 to 10 functional groups, and a long-chain aliphatic diol represented by HO-R1-OH wherein R1 represents a linear or branched, saturated or unsaturated alkylene group containing 30 to 150 carbon atoms, and
a hard segment composed of polycarbodiimide derived from an aromatic diisocyanate compound, the hard segment bonding to the soft segment through a urethane bond, and
wherein an end isocyanate remaining as an end of the hard segment is capped with an end-capping agent, and the polyol is castor oil or a castor oil-based polyol having 2 to 10 functional groups.
US Pat. No. 11,031,035

MAGNETIC TAPE HAVING CHARACTERIZED MAGNETIC LAYER AND MAGNETIC RECORDING AND REPRODUCING DEVICE

FUJIFILM Corporation, To...

1. A magnetic tape comprising a magnetic layer containing a ferromagnetic powder and a binding agent on a non-magnetic support,wherein the magnetic layer contains an oxide abrasive,
an average particle diameter of the oxide abrasive obtained from a secondary ion image acquired by irradiating a surface of the magnetic layer with a focused ion beam is 0.04 ?m to 0.08 ?m, and
an absolute value ?N of a difference between a refractive index Nxy measured with respect to an in-plane direction of the magnetic layer and a refractive index Nz measured with respect to a thickness direction of the magnetic layer is 0.25 to 0.40.
US Pat. No. 11,026,938

THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT

Britannia Pharmaceuticals...

1. A pharmaceutical composition for parenteral administration by injection having an active substance and being provided in the form of a solution, the pharmaceutical composition comprising:i) apomorphine as the active substance;
ii) a water miscible co-solvent;
iii) an antioxidant;
iv) water;
v) optionally, a surfactant; and
vi) optionally, a pH modifier;
wherein a pH of the pharmaceutical composition is greater than 4, and
wherein the pharmaceutical composition is administrable through a needle with a 27 Gauge or larger.
US Pat. No. 11,028,218

POLYOL COMPOSITIONS, A PROCESS FOR THE PRODUCTION OF THESE POLYOL COMPOSITIONS, AND THEIR USE IN THE PRODUCTION OF OPEN CELLED POLYURETHANE FOAMS HAVING HIGH AIRFLOW

Covestro LLC, Pittsburgh...

1. A process for the production of an open celled, flexible polyurethane foam comprising(I) preparing an isocyanate-reactive component comprising (a) an in-situ formed polyol blend having an overall hydroxyl number of from about 56 to about 250, and an average functionality greater than 2, and preparing said in-situ formed polyol blend by
A) introducing into a reaction vessel a mixture comprising:
(1) an initial starter (Si) comprising one or more monofunctional compounds having a hydroxyl number of less than about 56 and containing less than 20% by weight of copolymerized oxyethylene, based on 100% by weight of said one or more monofunctional compounds,
and
(2) a double metal cyanide (DMc) catalyst,
B) feeding
(1) an epoxide component comprising propylene oxide and ethylene oxide in a weight ratio of from 100:0 to 20:80,
into the reaction vessel;
C) allowing said epoxide component and the initial starter (Si) to react and continue to polymerize by feeding said epoxide component until the equivalent weight of said one or more monofunctional compound is increased by at least 10% by weight and reaches a value between about 1,500 and about 6,000;
D) continuously adding
(1) one or more low molecular weight starters (Sc) having a functionality of greater than 2 to about 6 and an equivalent weight of about 28 to about 400
into the reaction vessel while continuing to feed said epoxide component;
E) completing addition of the continuous starter (Sc);
and
F) allowing the mixture to continue to polymerize in the reaction vessel until said in-situ formed polyol blend has an overall hydroxyl number of from about 56 to about 250, an average functionality of greater than 2, and comprises
(1) one or more polyether monols having a hydroxyl number of less than 56, and containing less than 20% by weight of copolymerized oxyethylene, based on 100% by weight of F)(1);
and
(2) one or more polyether polyols having a hydroxyl number of about 47 to about 300, an average functionality of greater than 2 to about 6, and containing from about 5 to about 45% by weight of copolymerized oxyethylene, based on 100% by weight of F)(2);
wherein F)(1) and F)(2) are each present in the in-situ formed polyol blend in an amount of from about 25 to 75% by weight, with the combined weight of F)(1) and F)(2) totaling 100% by weight of said in-situ formed polyol blend;
(II) forming a polyol composition by blending or mixing (a) said in-situ formed polyol blend, with
(b) one or more polyether polyols having a functionality of 2 to 8, a hydroxyl number of 20 to 240 and comprising at least 50% of copolymerized oxyethylene, based on 100% by weight of component (b);wherein (a) said in-situ formed polyol blend is provided in an amount of from 20 to 98% by weight, and (b) said one or more polyether polyols is provided in an amount of from 2 to 80% by weight;(III) reacting an isocyanate-functional component with said polyol composition which comprises (a) said in-situ formed polyol blend, in the presence of a blowing agent, a catalyst, and a surfactant, wherein the isocyanate-functional component and the polyol composition are reacted at an isocyanate index of 85 to 120.
US Pat. No. 11,026,939

HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS, AND KITS RELATED THERETO

Neurocrine Biosciences, I...

1. A unit dosage form comprising:(S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester ditosylate;
silicified microcrystalline cellulose;
isomalt;
hydroxypropyl methylcellulose;
partially pregelatinized maize starch; and
magnesium stearate;
wherein (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester ditosylate is present at a level ranging from about 20 mg to 160 mg as measured as the free base, and
(S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester ditosylate is present at a level of at least 30% by weight of the total weight of the unit dosage form.
US Pat. No. 11,028,219

COMPOSITIONS FOR POLYURETHANE APPLICATIONS

HEXION INC., Columbus, O...

1. A polyol composition formed from a reaction mixture, comprising:a triazine-arylhydroxy-aldehyde condensate;
at least one alkylene carbonate; and
an optional catalyst.
US Pat. No. 11,026,428

BIOACTIVE MATERIAL

CALIX LTD, New South Wal...

1. A chemical composition for use as a biocide comprising a powder of micron scale calcined particles comprising a mixture ofa) at least one calcined carbonate compound containing oxygen defects selected from the group consisting of magnesite and dolomite, wherein the at least one calcined carbonate compound results from calcining at a temperature of about 750° C.;
b) at least one calcined hydroxide compound selected from the group consisting of brucite and magnesium hydroxide, wherein the at least one calcined hydroxide compound results from calcining at a temperature that is about 450° C.; and
(c) at least one component selected from the group consisting of ground limestone, lime, and hydrated lime,
wherein the particle size distribution of the powder is 0.4-10 microns, the particles have a porosity of greater than 0.5 and wherein the pore surface is largely composed of nano-crystalline structures.
US Pat. No. 11,026,940

COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME

Ampio Pharmaceuticals, In...

1. A composition, comprising:a low molecular weight fraction of a human serum albumin pharmaceutical composition comprising aspartyl-alanyl diketopiperazine (DA-DKP), N-acetyl tryptophan, and caprylate and/or caprylic acid, wherein:
albumin has been removed by filtration;
the molecular weight of the fraction is less than 5000;
the fraction comprises DA-DKP; and
a cell culture medium supplemented with said supplement is capable of supporting the expansion of stem cells.
US Pat. No. 11,026,941

CONCENTRATED, INHALABLE CIPROFLOXACIN FORMULATION

GRIFOLS, S.A., Los Angel...

1. A method of treating bronchiectasis in a patient, comprising:administering to lungs of the patient an aerosolized formulation comprising:
free unencapsulated ciprofloxacin;
a pharmaceutically acceptable excipient; and
liposome-encapsulated ciprofloxacin wherein the liposomes are unilamellar, have an average particle size of 1 nanometer to 10 microns, and comprise cholesterol and hydrogenated soy phosphatidyl-choline (HSPC);
wherein the liposomes maintain integrity when aerosolized and provide a ciprofloxacin release rate of 0.5% to 20% per hour over a period of time of 1-12 hours.
US Pat. No. 11,028,221

PET POLYMER WITH AN ANTI-CRYSTALLIZATION COMONOMER THAT CAN BE BIO-SOURCED

1. A method to prepare a PET polymer comprising:diacid units derived from diacid compounds, said diacid units comprising:
a) from 96.14 mol % to 97.15 mol % of said diacid units being terephthalic acid (TA) units or an ester thereof, and
b) from 2.85 mol % to 3.86 mol % of said diacid units being 2,5-furandicarboxylic acid (2,5-FDCA) units or an ester thereof, based on 100 mol % of all diacid units, and
diol units derived from diol compound(s), said diol units comprising monoethylene glycol units in an amount of at least 95.00 mol % of the diol units and optionally diethylene glycol units in an amount of less than 5.00 mol % of the diol units, based on 100 mol % of all diol units, comprising copolymerizing a mixture of:
the diacid compounds comprising terephthalic acid (TA) or an ester thereof, and 2,5-furandicarboxylic acid (2,5-FDCA) or an ester thereof, and
the diol compound(s), wherein the diol compound(s) comprise at least 95.00 mol % of monoethylene glycol of said diol compound(s) based on 100 mol % of all diol compound(s),wherein copolymerizing comprises a first step of melt polymerization and a second step of solid state polymerization,wherein the melt polymerization comprises a first sub-step of esterification or transesterification and a second sub-step of polycondensation,wherein the polycondensation is performed at a temperature of 285° C. in the presence of Sb2O3 as a catalyst.
US Pat. No. 11,026,942

AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE

KYOTO UNIVERSITY, Kyoto ...

1. A method for reducing A?42/A?40 ratio in the brain of a subject, comprising administering to the subject an effective amount of each of bromocriptine and topiramate,wherein
the effective amount of each of bromocriptine and topiramate is not more than a maximum nontoxic dose of each of bromocriptine and topiramate, and
the A?42/A?40 ratio in the brain of the subject is reduced relative to the A?42/A?40 ratio in the brain of the subject in the absence of administering bromocriptine and topiramate to the subject.
US Pat. No. 11,026,945

PROTEIN KINASE RNA-LIKE ENDOPLASMIC RETICULUM KINASE (PERK) INHIBITORS FOR PREVENTION AND/OR TREATMENT OF LUNG INJURY AND/OR INFLAMMATION

The Trustees of the Unive...

1. A method of treating lung injury and/or lung inflammation in a subject comprising administering to the subject a therapeutically effective dose of a PERK inhibitor to treat the lung injury and/or inflammation, wherein the PERK inhibitor is 1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl]-2-(3-trifluoromethylphenyl)ethanone.
US Pat. No. 11,027,458

PREPREG, METAL-CLAD LAMINATE, PRINTED WIRING BOARD, AND METHOD FOR PRODUCING PREPREG

PANASONIC INTELLECTUAL PR...

3. A metal-clad laminate comprising:an insulating layer formed of a cured product of the prepreg according to claim 1; and
a metal layer disposed on one or both surfaces of the insulating layer.
US Pat. No. 11,028,228

PROCESS FOR PRODUCING SPERHICAL POLYSILSESQUIOXANE PARTICLES

WACKER CHEMIE AG, Munich...

1. A process for improving batch to batch reproducibility in a process for producing spherical polysilsesquioxane particles, where a trialkoxysilane raw material contains differing amounts of chlorine compounds in different batches, the process comprising: in a first step, reacting trialkoxysilane T which contains trialkoxysilanes of formula (I)RSi(OR1)3  (I),
in which
R represents a hydrocarbon radical having 1 to 16 carbon atoms whose carbon chain may be interrupted by nonadjacent groups —O—,
R1 represents a C1- to C4-alkyl radical,
and which contains chlorine compounds,
by mixing the trialkoxysilane T with acidified water having a pH of at most 6 to afford a hydrolyzate,
in a second step the hydrolyzate is mixed with a solution of a base in water or C1-C4 alkanol,
and in a third step the mixture is stored for at least 2 h before isolating polysilsesquioxane particles,
wherein following the first step, the pH of a hydrolysate produced in the first step is measured and compared with a selected value, and if different from the selected value, the pH of the hydrolysate is adjusted to reduce the difference between the pH of the hydrolysate and the selected value.
US Pat. No. 11,028,229

METHOD FOR MAKING AN AMINO-FUNCTIONAL POLYDIORGANOSILOXANE USING A REMOVABLE ACID CATALYST

Dow Silicones Corporation...

1. A method for preparing an amino-functional polydiorganosiloxane comprising:1) mixing and heating, at a temperature of 50° C. to 150° C., starting materials comprising
A) a silanol functional polydiorganosiloxane,
B) an aminoalkyl-functional alkoxysilane,
where amounts of starting materials A) and B) are such that a molar excess of silanol groups with respect to alkoxy groups is present, and
C) 0.1% to 0.5%, based on combined weights of all starting materials, of an endblocker having triorganosilyl groups; and thereafter
2) adding starting material D) 0.01% to 5%, based on weight of starting material B), of a carboxylic acid having a boiling temperature of 90° C. to 150° C. and pKa value of 1 to 5; thereby forming a reaction mixture;
3) mixing and heating the reaction mixture to form the reaction product and reduce amount of residual acid in the form of the carboxylic acid and/or carboxylate salt to 0 to <500 ppm, based on the weight of the amino-functional polydiorganosiloxane.
US Pat. No. 11,026,438

CONFECTIONERY PRODUCT AND METHOD OF MAKING

THE HERSHEY COMPANY, Her...

1. A method of forming a confectionery product comprising:providing a first confectionery mass of a molten hard candy composition;
providing a second confectionery mass of a non-hard candy composition;
contacting the first confectionery mass in a molten state and the second confectionery mass at a nozzle outlet to form a combined stream, the first confectionery mass being at a first temperature and having a first viscosity and the second confectionery mass being at a second temperature in the range of 60° C. to 120° C. and having a second viscosity within 1500 cP of the first viscosity; then
vertically filling a cavity by co-depositing the first and second confectionery masses as the combined stream into the cavity to form a laminate of alternating overlapping layers of the confectionery masses;
cooling the co-deposited masses in the cavity to form the confectionery product; and
removing the confectionery product from the cavity.
US Pat. No. 11,028,230

METHOD FOR CONDENSATION POLYMERIZATION OF HYDROXYL-TERMINATED POLYDIORGANOSILOXANES

Dow Silicones Corporation...

1. A method for polymerizing polydiorganosiloxanes comprising:1) heating, at a temperature of 50° C. to 200° C., a reaction mixture prepared by mixing starting materials comprising
A) a polydiorganosiloxane of unit formula [(HO)R2SiO1/2]2(R2SiO2/2)n, where subscript n is 0 to 2000, and each R is an independently selected monovalent hydrocarbon group of 1 to 18 carbon atoms; and
B) 10 ppm to 500 ppm, based on weight of starting material A), of a trifluoromethane sulfonate compound selected from the group consisting of
B-1) aluminum(III) trifluoromethanesulfonate,
B-2) bismuth(III) trifluoromethane sulfonate,
B-3) gallium(III) trifluoromethane sulfonate,
B-5) indium(III) trifluoromethane sulfonate,
B-6) scandium(III) trifluoromethane sulfonate, and
B-7) dicyclohexylboron trifluoromethanesulfonate;
2) quenching the reaction mixture; and
3) recovering a product from the reaction mixture, where the product has unit formula [(HO)R2SiO1/2]2(R2SiO2/2)m, where m>n.
US Pat. No. 11,027,975

METHOD TO MAKE PHOSPHORIC ACID AND AMMONIUM PHOSPHATES FROM PHOSPHATE MINERALS

Wisconsin Alumni Research...

11. A method of producing phosphoric acid comprising:(a) isolating from a water stream at least one mineral, wherein the mineral comprises phosphate and at least one element selected from the group consisting of calcium, magnesium, iron, and aluminum, and wherein the mineral requires from 30 to 1000 mass parts of water of pH 7.0 to one mass part of the mineral to dissolve the mineral and has increased solubility in acidic water having a pH range from about 2.0 to less than 7.0; and
(b) contacting the at least one mineral with a cation exchanger for a time and at a temperature sufficient to yield phosphoric acid from the mineral.
US Pat. No. 11,028,231

POLYSILOXANE COMPRISING SUBSTITUENTS HAVING MULTIPLE ARYL GROUPS

Dow Silicone Corporation,...

1. A polysiloxane comprising: (a) from 40 to 90 mole % units of formula R1R2SiO2/2, (b) from 30 to 60 mole % units of formula R3SiO3/2, and (c) from 0 to 5 mole % units of formula R?R4SiO2/2; wherein R1 and R2 independently are phenyl or C1-C6 alkyl; R3 represents at least one C1-C30 hydrocarbyl group; R4 is —Ar1-X—Ar2, where Ar1 and Ar2 independently are C6-C12 aryl and X is O or CH2; provided that the polysiloxane comprises at least one —Ar1-X—Ar2 group.
US Pat. No. 11,026,952

SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION

President and Fellows of ...

1. A method of increasing satellite cell proliferation, the method comprising: contacting a satellite cell with a p38 MAPK inhibitor selected from the group consisting of SB 239063 (trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; HMSL10036-101-1); Doramapimod (BIRB 796; HMSL10169-101-1); SB 203580 (RWJ 64809; PB 203580; HMSL10167-101-1); Neflamapimod (VX-745; HMSL10168-101-1); PH-797804 (HMSL10439-101); VX-702 (HMSL10440-101); SB202190 (HMSL10441-101); Ralimetinib (LY2228820; HMSL10438-103); Losmapimod (GSK-AHAB; SB856553; GW856553X; HMSL10402-101); and any combinations thereof.
US Pat. No. 11,026,441

AVOCADO FLESH AND/OR SKIN EXTRACT RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME

LABORATOIRES EXPANSCIENCE...

1. A method for preventing and/or treating allergic, inflammatory or irritative reactions of the skin and/or mucous membranes and/or appendages, or for preventing and/or treating disorders or pathologies of the skin barrier, or homeostasis of the skin, comprising administering to a subject in need thereof an effective amount of a cosmetic, pharmaceutical, dermatological, or nutraceutical composition comprisinga polyphenol-rich extract of avocado fruit, comprising at least 10% polyphenols by weight, expressed in gallic acid equivalents in relation to the dry extract, and comprising 0 to 10% by weight of avocado lipids in relation to the dry extract, wherein the polyphenols comprise a mixture of procyanidins, caffeic acid and derivatives of caffeic acid, wherein the mixture is at least 70% by weight, expressed in gallic acid equivalents, in relation to total polyphenol content by weight, and wherein the mixture contains at least 20% caffeic acid and derivatives of caffeic acid and at least 30% procyanidins by weight, expressed in gallic acid equivalents, in relation to total polyphenol content by weight,
wherein the extract further comprises at least 10% avocado sugars by weight in relation to the weight of the dry extract, said sugars containing at least D-mannoheptulose and/or perseitol, and
wherein the extract further comprises 1 to 30% avocado proteins by weight in relation to the weight of the dry extract, and
a suitable carrier.
US Pat. No. 11,026,953

3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN TREATMENT OF ESSENTIAL TREMOR

ASARINA PHARMA AB, Solna...

1. A method of treating essential tremor in a patient, comprising administering an effective amount of 3beta-hydroxy-5alpha-pregnan-20-one, to the patient.
US Pat. No. 11,028,233

METHOD FOR MAKING AN AMINO-FUNCTIONAL POLYDIORGANOSILOXANE USING A REMOVABLE SOLID CATALYST

Dow Silicones Corporation...

1. A method for preparing an amino-functional polydiorganosiloxane comprising:1) mixing and heating, at a temperature of 50° C. to 160° C., starting materials comprising
A) a silanol functional polydiorganosiloxane,
B) an aminoalkyl-functional alkoxysilane, where amounts of starting materials A) and B) are such that a molar excess of silanol groups with respect to alkoxy groups is present, and
C) 0 to 0.5%, based on combined weights of all starting materials, of an endblocker having triorganosilyl groups; and thereafter
2) providing starting material D) 0.01% to 5%, based on weight of starting material B), of a solid (at conditions of 20° C. to 25° C. and 101 kPa) precatalyst selected from the group consisting of a carboxylic acid, an acid anhydride, and a combination of both the carboxylic acid and the acid anhydride under conditions permitting the precatalyst to react to form a catalyst; thereby forming a reaction mixture; and
3) mixing and heating the reaction mixture under conditions to form a reaction product; and
4) removing all or a portion of residual acid by a technique comprising cooling the reaction product, thereby reducing amount of the residual acid to 0 to <500 ppm, based on the weight of the amino-functional polydiorganosiloxane, where step 4) further comprises filtering and/or centrifuging the reaction product after cooling.
US Pat. No. 11,028,234

ADDITION-CURABLE SILICONE COMPOSITION

SHIN-ETSU CHEMICAL CO., L...

1. An addition curable silicone composition comprising:(A) an organopolysiloxane containing at least two aliphatic unsaturated hydrocarbon groups per molecule and having a kinematic viscosity of 60 to 100,000 mm2/s at 25° C.,
(B) an organohydrogenpolysiloxane having at least two silicon-bonded hydrogen atoms per molecule, in such an amount that a ratio of the number of Si—H groups to the total number of aliphatic unsaturated hydrocarbon groups in component (A) ranges from 0.5 to 5, and
(C) an effective amount of a microparticulate hydrosilylation catalyst of microcapsule structure consisting of a core material of an organic compound or polymer containing a platinum group metal catalyst and a shell material of a three-dimensional crosslinked polymer obtained by polymerizing at least one polyfunctional monomer, the organic compound or polymer containing a platinum group metal catalyst having a kinematic viscosity of 10 to 100,000 mm2/s at 25° C.,
wherein the polyfunctional monomer is a polyfunctional monomer having at least two polymerizable carbon-carbon double bonds per molecule.
US Pat. No. 11,027,467

FLUORINATED COPOLYMER COMPOSITION, METHOD FOR ITS PRODUCTION, AND MOLDED PRODUCT

AGC Inc., Chiyoda-ku (JP...

1. A fluorinated copolymer composition comprising the following thermoplastic resin A and the following fluorinated elastomer B, whereinthe fluorinated elastomer B is dispersed in the thermoplastic resin A,
the number average particle diameter of the fluorinated elastomer B is from 1 to 300 ?m, and
the volume ratio of the thermoplastic resin A to the fluorinated elastomer B is from 97:3 to 55:45, and
having a flexural modulus of from 1,000 to 3,700 Mpa,
wherein the thermoplastic resin A is at least one type of melt-moldable thermoplastic heat-resistant resin selected from the group consisting of a polyarylate, a polyether sulfone, a polyaryl sulfone, an aromatic polyamide, an aromatic polyether amide, an aromatic polyether imide, a polyphenylene sulfide, a polyaryl ether ketone, a polyamideimide and a liquid crystal polyester,
wherein the fluorinated elastomer B is at least one type of fluorinated elastic copolymer selected from the group consisting of a copolymer having units based on tetrafluoroethylene and units based on propylene, a copolymer having units based on hexafluoropropylene and units based on vinylidene fluoride, and a copolymer having units based on tetrafluoroethylene and units based on a perfluoro(alkyl vinyl ether), and the perfluoro(alkyl vinyl ether) is a compound represented by the following formula (I),
CF2?CF(ORF)  (I)
wherein RF is a C1-8 linear or branched perfluoroalkyl group and wherein the fluorinated elastomer B has a Mooney viscosity (ML1+10, 121° C.) of from 20 to 200.
US Pat. No. 11,026,956

CANCER DRUG AND USES

Health Clinics Limited, ...

1. A pharmaceutical kit comprising an anti-diabetic drug, a statin, and a glycolysis inhibitor.
US Pat. No. 11,027,980

ALUMINA-MODIFIED COLLOIDAL SILICA PARTICLES, CEMENTITIOUS PRODUCTS CONTAINING SAME, AND METHODS OF USE THEREOF

Intelligent Concrete, LLC...

1. A method of forming a cementitious composition comprising mixing water, cement and an additive comprising colloidal silica nanoparticles that are at least partially coated in alumina in an aqueous solution.
US Pat. No. 11,026,957

METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS

SRX CARDIO, LLC, Pittsfo...

1. A method comprising; binding an allosteric small molecule compound to a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) protein of a subject with a lipid dysregulation to modulate the uptake of low-density lipoprotein by a plurality of hepatocytes.
US Pat. No. 11,027,981

PROCESS FOR THE PREPARATION OF SILICATE AND ITS USE FOR THE PREPARATION OF PRECIPITATED SILICA

RHODIA OPERATIONS, Paris...

1. A process for the preparation of a silicate S2, the process comprising: reacting rice husk ash with at least one silicate precursor P1 to obtain a silicate S2 having a SiO2/MxO molar ratio MR2, wherein the at least one silicate precursor P1 is either: a silicate S1 having a SiO2/MxO molar ratio MR1, such that MR2>MR1; or a mixture of sand with at least one metal hydroxide;wherein M is a metal selected from the group consisting of alkaline metals and x is 2;
wherein, when silicate precursor P1 is the silicate S1, the method further comprises preparing the silicate S1 by direct attack of said with an alkali hydroxide.
US Pat. No. 11,028,749

HYDROGEN REDUCTANT FOR CATALYTIC POLLUTION ABATEMENT

BASF CORPORATION, Florha...

1. A system for abatement of pollutants in an exhaust gas stream of an internal combustion engine, the system comprising:a catalytic article downstream of and in fluid communication with the internal combustion engine;
a hydrogen generation system comprising an ammonia decomposition article configured to generate hydrogen, the ammonia decomposition article comprising an ammonia/organic solvent reservoir or an ammonia storage tank, and a catalytic reactor configured to collect hydrogen from ammonia;
a hydrogen injection article in fluid communication with the catalytic article and with the exhaust gas stream of the internal combustion engine and configured to introduce hydrogen into the exhaust gas stream upstream of the catalytic article; and
optionally, a hydrogen storage article.
US Pat. No. 11,026,959

SYNTHETIC COMPOSITION AND METHOD FOR TREATING IRRITABLE BOWEL SYNDROME

1. A method comprising:selecting an adult human patient with irritable bowel syndrome (IBS) experiencing one or more IBS symptoms;
selecting an amount of a mixture of 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT) effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the adult human patient; and
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the adult human patient and reducing the likelihood of the adult human patient experiencing the one or more IBS symptoms by administering a daily dose of the selected effective amount of the mixture of 2?-FL and LNnT to the adult human patient.
US Pat. No. 11,028,239

MANUFACTURING METHOD FOR LOW MOLECULAR WEIGHT POLYTETRAFLUOROETHYLENE, AND POWDER

DAIKIN INDUSTRIES, LTD., ...

1. A method for producing low molecular weight polytetrafluoroethylene, comprising:(1) feeding into an airtight container:
high molecular weight polytetrafluoroethylene: and
a gas mixture containing an inert gas and oxygen and having an oxygen content relative to the total of the inert gas and oxygen of 1 to 5 vol %; and
(2) irradiating the high molecular weight polytetrafluoroethylene to provide low molecular weight polytetrafluoroethylene having a melt viscosity at 380° C. of 1.0×102 to 7.0×105 Pa·s,
wherein the low molecular weight polytetrafluoroethylene contains perfluorooctanoic acid and salts thereof in a total amount by mass of not more than 20 ppb.
US Pat. No. 11,028,240

COMPOSITE MATERIALS WITH DESIRED CHARACTERISTICS

Nanocore APS, Roskilde (...

1. A composite material comprising a composition of at least 1016 composite material units (CMUs), where each of the CMUs has the structure (SE1-Ligand1-LinkerL-Ligand2-SE2), where SE1 and SE2 are structural entities, Ligand1 and Ligand2 are chemical entities which are bound to SE1 and SE2, respectively, and whereSE1 is a carbon nanotube,
SE2 is a polyamide, polycarbonate, polystyrene, an epoxy-based polymer, polyethylene terephthalate, polyvinylchloride, polyacrylate, or polyolefin;
Ligand1 is a chemical entity that is capable of binding non-covalently to SE1, wherein
Ligand1 comprises one or more natural amino acids,
Ligand2 is a bond capable of binding covalently to SE2, and
LinkerL is a chemical bond or entity that covalently links Ligand1 and Ligand2.
US Pat. No. 11,026,961

USE OF BIOSURFACTANT

HIROSHIMA UNIVERSITY, Hi...

1. A method for ameliorating or treating mastitis, comprising topically applying an effective amount of a biosurfactant to an udder of a ruminant in need thereof at a frequency of at least once a day for at least 7 days.
US Pat. No. 11,026,962

BETALAIN COMPOSITIONS AND METHODS THEREFOR

VDF Futureceuticals, Inc....

1. A method of reducing joint pain in an individual, comprising:administering or providing for administration a dehydrated complex betalain mixture comprising a plurality of distinct betalains from a starting material, wherein the distinct betalains have a near natural composition and are present in the mixture at a total betalain concentration of at least 4 wt %;
wherein the dehydrated complex betalain mixture further comprises a plurality of sugars, wherein a ratio of the plurality of distinct betalains to the one or more sugars is at least 0.3; and
wherein the complex betalain mixture is formulated for oral administration and orally administered in an amount that reduces joint pain in the individual.
US Pat. No. 11,027,218

PURIFICATION AND SEPARATION TECHNIQUES FOR CANNABINOIDS

Canopy Growth Corporation...

1. A method of purifying one or more cannabinoids from a plant material of genus cannabis, comprising:adding the plant material of genus cannabis to ethanol;
sonicating the ethanol and plant material of genus cannabis at a temperature of between about ?80 to 30 degrees Celsius;
dissolving cannabinoids in the ethanol to create a solution of cannabinoids;
physically separating the plant material of genus cannabis from the solution comprising cannabinoids; and
evaporating the ethanol from the solution at a pressure of less than 1 atmosphere.
US Pat. No. 11,027,219

FURAN-2, 5-DICARBOXYLIC ACID PURGE PROCESS

Eastman Chemical Company,...

1. A process to produce an impurity rich waste stream in a carboxylic acid process, said process comprising:contacting a mother liquor in a solvent recovery zone to produce said impurity rich waste stream; wherein said mother liquor stream comprises at least one of the following:
(i) 2,5-diformylfuran in an amount ranging from about 20 ppm to about 2.0 wt %,
(ii) levulinic acid in an amount ranging from about 20 ppm to about 2.0 wt %,
(iii) succinic acid in an amount ranging from about 20 ppm to about 2.0 wt %, and
(iv) acetoxy acetic acid in an amount ranging from about 20 ppm to about 2.0 wt %,
wherein said process further comprises routing a portion of said impurity rich waste stream to a solid-liquid separation zone comprising at least one continuous pressure drum filter to form a purge mother liquor stream.
US Pat. No. 11,028,243

ORIENTED POLYESTER FILM

TOYOBO CO., LTD., Osaka ...

1. An oriented polyester film containing antioxidant and modified polyolefin wax in a surface layer on at least one side thereof, wherein the oriented polyester film is such that the modified polyolefin wax contained in said layer is present in an amount that, as measured based on weight of a composition at said layer, is not less than 0.1 wt % but less than 3.0 wt %, and wherein the modified polyolefin wax is such that acid value thereof is not less than 1 mg KOH/g but less than 50 mg KOH/g, 3 wt % weight loss onset temperature thereof is not less than 300° C., weight-average molecular weight thereof is within a range that is 3,500 to 65,000, and the antioxidant is present in an amount that, as measured based on the weight of the composition, is not less than 0.02 wt % but less than 0.35 wt %.
US Pat. No. 11,026,964

DELIVERY OF RNA TO DIFFERENT CELL TYPES

GLAXOSMITHKLINE BIOLOGICA...

1. A method of administering to a delivery site in a vertebratea pharmaceutical composition, in an immunologically effective amount to raise an effective immune response to a pathogen in the vertebrate, comprising immunogen encoding RNA encapsulated within liposomes and immunogen encoding RNA on the surface of liposomes, wherein at least half of the RNA is liposome-encapsulated, and wherein the RNA has a size of about 5000-25000 nucleotides and is not virion-packaged, and wherein the liposomes have an aqueous core,
and then permitting immune cells to infiltrate the delivery site, such that the RNA separately enters both (a) non-immune cells at the delivery site and (b) the infiltrating immune cells, provided that the RNA includes no modified nucleotides other than a 5? cap.
US Pat. No. 11,026,966

ANIMAL FEED PRODUCTS CONTAINING PERCARBONATE AND METHODS OF FEEDING SAME

PURINA ANIMAL NUTRITION L...

1. A method of feeding livestock animals, the method comprising:feeding the livestock animals a milk replacer comprising an antibacterial system consisting of percarbonate and at least one added acid selected from a group consisting of: citric acid, malic acid, valeric acid, acetic acid, propionic acid, butyric acid, formic acid, caproic acid, oxalic acid, lactic acid, benzoic acid, carbonic acid, phosphoric acid, hydrochloric acid, sulfuric acid, succinic acid, tartaric acid, fumaric acid, adipic acid, gluconic acid, pyrophosphoric acid and carbolic acid, wherein the milk replacer has a reduced pH of about 5.8,
wherein the milk replacer exhibits reduced growth of Salmonella over a period of about 2 to about 8 hours relative to a milk replacer of pH 5.8 that lacks percarbonate.
US Pat. No. 11,026,967

COMPOSITION FOR SUPPRESSING OR PREVENTING ABNORMALITY IN INTESTINAL ENVIRONMENT

MIZ COMPANY LIMITED, Kan...

1. A method of suppressing or preventing bacterial translocation in the intestinal environment in a subject, comprising administering to a subject in need thereof a composition comprising dissolved hydrogen as an active ingredient, such that bacterial translocation is suppressed or prevented in the intestinal environment of the subject.
US Pat. No. 11,028,247

PROCESS FOR PRODUCING POROUS ALGINATE-BASED AEROGELS

BASF SE, Ludwigshafen (D...

1. A porous material obtained by a process comprising:a) providing a mixture (I) comprising
(i) a water soluble polysaccharide,
(ii) a compound which reacts as a cross-linker for the water soluble polysaccharide or which releases a cross-linker for the water soluble polysaccharide, and
(iii) water;
b) preparing a gel (A) by a process comprising
b1) exposing the mixture (I) to carbon dioxide at a pressure of from 20 to 100 bar for a time sufficient to form a gel (A), and
b2) depressurizing the gel (A);
c) exposing the gel (A) to a water miscible solvent (L) to obtain a gel (B); and
d) drying the gel (B),
wherein the water miscible solvent (L) is at least one selected from the group consisting of a C1 to C6 alcohol a C1 to C6 ketone, and a mixture thereof,wherein the water soluble polysaccharide is an alginate, and wherein the compound which reacts as a cross-linker for the water soluble polysaccharide or which releases a cross-linker for the water soluble polysaccharide in the mixture (I) comprises calcium carbonate,wherein the porous material has a pore volume in the range of from 2.1 to 9.5 cm3/g for pore sizes <150 nm.
US Pat. No. 11,027,992

IRON-BASED AMORPHOUS ELECTRODE MATERIAL FOR WASTEWATER TREATMENT AND USE THEREOF

1. An iron-based amorphous electrode for industrial wastewater treatment, wherein the iron-based amorphous electrode is made of an iron-based amorphous alloy, wherein the iron-based amorphous electrode defines a ribbon, wherein the atomic percentage of iron element in the iron-based amorphous alloy is 65% to 84%, and the remaining alloying element is one or more elements selected from the group consisting of P, C, Mo, Ni and Co.
US Pat. No. 11,028,248

SYSTEM AND PROCESS FOR RECYCLING CONTAMINATED POLYOLEFINS

1. A method of recycling contaminated polyolefins, including removal of contaminants from a contaminated polyolefin material, comprising:swelling a contaminated polyolefin material with a solvent causing contaminants in the polyolefin material to dissolve in the solvent; and
removing the solvent and the contaminants in the solvent from the polyolefin material, whereby removing the contaminants dissolved in the solvent from the polyolefin material includes a compression of the swollen polyolefin material, through which a majority of the solvent is pressed out of the swollen polyolefin material.
US Pat. No. 11,026,969

HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF

Fred Hutchinson Cancer Re...

1. A binding protein, comprising:(a) a T cell receptor (TCR) ?-chain variable (V?) domain having a CDR3 amino acid sequence shown in any one of SEQ ID NOS.:93-102, and a TCR ?-chain variable (V?) domain; or
(b) a V?domain of (a) and a V?domain having a CDR3 amino acid sequence shown in any one of SEQ ID NOS.:105-114;
wherein the binding protein is capable of specifically binding to a WT-1 peptide:HLA complex on a cell surface independent of CD8 or in the absence of CD8.
US Pat. No. 11,026,970

METHODS AND TREATMENT OF TRAUMA ADVERSE EVENTS WITH OXYGEN REDUCED BLOOD

Hemanext Inc., Lexington...

1. A method of reducing the risk of organ damage in a hemorrhagic trauma adverse event in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level compared to an oxygen saturation level prior to storage for a storage period, wherein said risk of organ damage is reduced relative to a patient receiving conventionally stored blood.
US Pat. No. 11,028,250

COMPOSITION WITH THERMAL CONDUCTIVITY AND LASER PLATING PERFORMANCE BY CORE-SHELL STRUCTURE LDS ADDITIVE WITH METAL COMPOUNDS COATED ON MINERAL FILLER SURFACE

SHPP Global Technologies ...

1. A thermally conductive polymer composition comprising:a. from about 20 wt % to about 80 wt % of at least one polymer component, wherein the polymer component comprises a polycarbonate;
b. from greater than about 0 wt % to about 70 wt % of a thermally conductive filler; and
c. from about 0.1 wt % to about 40 wt % of a laser activatable additive having a core-shell structure; wherein the core comprises an inorganic filler and the shell comprises a laser activatable component,
wherein the combined weight percent value of all components does not exceed 100 wt %,
wherein all weight percent values are based on the total weight of the composition,
wherein a molded sample of the composition has a through plane thermal conductivity of at least about 0.40 W/m·K when determined in accordance with ASTM E1461, and wherein a molded sample of the composition exhibits a notched Izod impact strength of at least 66 J/m when tested in accordance with ASTM D256 at 23° C.
US Pat. No. 11,026,971

METHODS AND TREATMENT OF TRAUMA ADVERSE EVENTS WITH OXYGEN REDUCED BLOOD

Hemanext Inc., Lexington...

1. A method of reducing the risk of developing a hemorrhagic trauma adverse event in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said hemorrhagic trauma adverse event is liver injury and said risk is reduced relative to a patient receiving conventionally stored blood.
US Pat. No. 11,026,972

METHODS FOR GENERATING MACROPHAGES WITH ENHANCED CANCER PHAGOCYTOSIS

Georgia State University ...

1. A method of generating macrophages with enhanced cancer phagocytosis, the method comprising:(a) providing a biological sample from a subject, wherein the biological sample comprises macrophages;
(b) exposing the sample to an effective amount of a first composition comprising at least 100 units/ml IFN? to suppress the expression or activity of signal regulatory protein ? (SIRP?); and
(c) exposing the sample from step (b) to an effective amount of a second composition that activates Protein kinase C (PKC)-Spleen tyrosine kinase (Syk) pathway, thereby generating macrophages with enhanced cancer phagocytosis.
US Pat. No. 11,027,484

3D PRINTED FLUOROPOLYMER-BASED ENERGETIC COMPOSITIONS

Purdue Research Foundatio...

1. A 3D printed polyvinylidene fluoride (PVDF)-based energetic material comprising a plurality of layers that consist essentially of polyvinylidene fluoride (PVDF) and aluminum,wherein one or more layer of said a plurality of layers has a thickness of at least 200 ?m,
wherein the 3D printed polyvinylidene fluoride (PVDF)-based energetic material is substantially free of any other polymer and is prepared by a 3D printing method, wherein the method comprises:
a) preparing a pellet that consist essentially of polyvinylidene fluoride (PVDF) and aluminum;
b) preparing a filament by adding the pellet to a filament extruder; and
c) 3D printing the filament to provide the 3D printed polyvinylidene fluoride (PVDF)-based energetic material at a temperature below the onset to reaction temperature of polyvinylidene fluoride (PVDF).
US Pat. No. 11,031,583

COATING AND LITHIATION OF INORGANIC OXIDANTS BY REACTION WITH LITHIATED REDUCTANTS

BELENOS CLEAN POWER HOLDI...

1. A coated at least partially metallated particulate electroactive material that is crystalline or amorphous, obtained by a process comprising:premixing an oxidant electroactive material with a metallated reductant, followed by
chemically reacting the oxidant electroactive material with the metallated reductant,
wherein:
the metallated reductant is a coating precursor comprising an alkali metal or both an alkali metal and an alkaline earth metal,
the chemically reacting is performed under a condition allowing reduction and metallation of the oxidant electroactive material via insertion or intercalation of the alkali metal and/or the alkaline earth metal and coating of the metallated electroactive material with a coating formed from the metallated reductant, and
wherein the coating formed from the metallated reductant comprises at least one selected from the group consisting of:
carbon nitride formed from Li2CN2;
carbon boride formed from Li4BCB;
carbon boron nitride formed from a lithium pyrazine precursor;
polymeric sulfur nitride formed from Li9NS3; and
polyacetylene formed from LiHC2.
US Pat. No. 11,026,973

ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF

Myeloid Therapeutics, Inc...

1. A pharmaceutical composition comprising:(a) myeloid cells from a human subject comprising a recombinant polynucleic acid, wherein the myeloid cells are CD14+ and CD16?, and wherein the recombinant polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:
(i) an extracellular domain comprising a CD5 binding domain, wherein the CD5 binding domain comprises an scFv comprising a variable heavy chain (VH) sequence with SEQ ID NO: 1 and a variable light chain (VL) sequence with SEQ ID NO: 2,
(ii) a CD8 transmembrane domain operatively linked to the extracellular domain; and
(iii) an intracellular domain comprising at least two intracellular signaling domains, wherein the at least two intracellular signaling domains comprise:
(A) a first intracellular signaling domain derived from Fc?R or Fc?R, and
(B) a second intracellular signaling domain comprising a PI3K recruitment domain; and
(b) a pharmaceutically acceptable carrier;
wherein the myeloid cells express the CFP and exhibit at least a 1.1 fold increase in phagocytosis of a target cell expressing CD5; and
wherein the pharmaceutical composition comprises an effective amount of the myeloid cells to inhibit growth of a solid tumor when administered to a human subject with the solid tumor.
US Pat. No. 11,026,974

RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES

Iovance Biotherapeutics, ...

1. A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs comprising:(i) performing a first expansion by culturing a first population of TILs obtained from a tumor resected from a patient;
in a cell culture medium comprising IL-2 to produce a second population of TILs; and
(ii) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the third population of TILs is at least 100-fold greater in number than the second population of TILs, and wherein the second expansion is performed for at least 14 days in order to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs which comprises an increased subpopulation of effector T cells and/or central memory T cells relative to the second population of TILs.
US Pat. No. 11,028,254

RUBBER COMPOSITION COMPRISING A SPECIFIC CRUMB RUBBER

COMPAGNIE GENERALE DES ET...

1. A rubber composition based on at least an elastomer, a reinforcing filler, a crosslinking system, and a crumb rubber,wherein the crumb rubber has an isoprene elastomer content of greater than 50 phr in the composition of the rubber crumb and a chloroform extract with a weight-average molecular weight of less than 10,000 g/mol.
US Pat. No. 11,026,975

CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO BCMA, AND USES THEREOF

Nanjing IASO Biotherapeut...

1. A chimeric antigen receptor (CAR), wherein the CAR comprises a B-cell maturation antigen (BCMA) binding domain, a transmembrane domain, a costimulatory domain and an intracellular signal transduction domain, the BCMA-binding domain comprises an antibody or a fragment thereof capable of specifically binding-a BCMA protein, and the antibody comprises a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2) and a heavy chain complementary determining region 3 (HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 9, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 10, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 11; and wherein the antibody comprises a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2) and a light chain complementary determining region 3 (LCDR3), and wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO: 17, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 18, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 19.
US Pat. No. 11,027,487

FUNCTIONAL SURFACE COATING METHODS FOR ADDITIVELY MANUFACTURED PRODUCTS

CARBON, INC., Redwood Ci...

1. A method of making a coated object, comprising:stereolithographically producing a green intermediate object from a dual cure polymerizable resin, wherein said polymerizable resin comprises: (a) a cyanate ester dual cure resin; or (b) an epoxy dual cure resin, said intermediate object containing uncured polymerizable material therein; then,
optionally cleaning said green object; then, in any order:
coating at least one surface portion of said object with a particulate material; and
heating said object sufficiently to further cure said object;
said coating and/or heating steps carried out under conditions in which uncured polymerizable material sweats or exudes to the surface of said object, and
wherein the uncured polymerizable material contacts said particulate material, polymerizes, and bonds said particulate material to the surface of said object during said coating and/or heating steps.
US Pat. No. 11,028,255

COMPOSITION FOR TIRE TREAD COMPRISING RESIN ALTERNATIVE TO PROCESS OIL

1. A composition for a tire tread, comprising at least one resin selected from the group consisting of a methylstyrenated phenol-based resin, and a hydrocarbon-based resin, and at least one resin selected from the group consisting of a terpene phenol resin and a hydrogenated hydrocarbon-based resin,wherein the methylstyrenated phenol-based resin and the hydrocarbon-based resin do not comprise a softening point measured by ASTM E 28, and
wherein the hydrogenated hydrocarbon-based resin and the terpene phenol resin comprise a softening point measured by ASTM E 28.
US Pat. No. 11,026,976

NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS COMPRISING A CD20 BINDING DOMAIN

Novartis AG, Basel (CH) ...

1. An isolated chimeric antigen receptor (CAR) molecule comprising a CD20 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD20 binding domain comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3) heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:(i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;
(ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;
(iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively;
(iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively;
(v) SEQ ID NOs: 228, 229, 230, 217, 218, and 219, respectively;
(vi) SEQ ID NOs: 231, 232, 233, 220, 221, and 222, respectively;
(vii) SEQ ID NOs: 234, 235, 236, 223, 224, and 225, respectively; or
(viii) SEQ ID NOs: 944, 945, 988, 941, 942, and 943, respectively.
US Pat. No. 11,027,232

METHODS FOR PRODUCING OZONE

Messer Industries USA, In...

1. A method for producing ozone from an oxygen and ozone mixture, comprising:separating ozone present in an oxygen and ozone mixture in concentrations ranging from 6% to 12% by adsorbing the ozone in an adsorbent separation system at a higher pressure, wherein the ozone adsorbed in an adsorbent is in equilibrium with ozone at the partial pressure of ozone in the oxygen and ozone mixture;
introducing a weakly adsorbed gas into the adsorption separation system;
contacting the weakly adsorbed gas with the adsorbent at a lower pressure than the higher pressure, thereby desorbing ozone at a partial pressure that is the same as that during adsorption, to thereby produce an ozone stream at a higher concentration than that present in the adsorption; and
transporting the desorbed ozone with the weakly adsorbed gas from the adsorption separation system.
US Pat. No. 11,028,000

METHOD FOR PREPARING ERIDITE ROD-SHAPED PARTICLES FOR WATER TREATMENT BY UTILIZING WASTEWATER

NORTHEAST NORMAL UNIVERSI...

1. A method for preparing Erdite rod-shaped particles for water treatment by utilizing iron-containing waste mud in an underground water plant, said method comprising the following steps:A. performing mechanical dehydration on aqueous iron mud, controlling a moisture content of the aqueous iron mud to be between 20% and 50%, to obtain a first aqueous iron mud;
B. adding sodium sulfide to the first aqueous iron mud to obtain a first mixture, wherein a weight of the first aqueous iron mud to a volume of sodium sulfide is between 3% and 15%;
C. adding to the first mixture a volume of water equal to a volume of the first mixture, airtight heating the first mixture with the added water at a constant temperature of 140° C.-270° C. for 0.5 hr to 4 hr; and
D. centrifuging the solution from step C to obtain a supernatant and a solid, and vacuum drying the solid at 40° C.-60° C. for 24 hr to obtain Erdite rod-shaped particles, wherein the Erdite is NaFeS2.2H2O; and recycling the supernatant for standby applications.
US Pat. No. 11,028,256

SILICA-CONTAINING RUBBER COMPOSITIONS CONTAINING SPECIFIED COUPLING AGENTS AND RELATED METHODS

Bridgestone Americas Tire...

1. A tire rubber composition comprising:(a) 100 phr of at least one conjugated diene-containing polymer,
(b) about 50 to about 120 phr reinforcing filler comprising silica or silica in combination with carbon black,
(c) a bi-functional sulfur-containing silane coupling agent, and
(d) an unsaturated, non-sulfur silane coupling agent, wherein the ratio of (c) to (d) is from about 5:1 to about 20:1 and wherein the bi-functional sulfur-containing silane coupling agent is a mercapto silane compound, a blocked mercapto silane compound, or a disulfide-based alkoxy-containing silane compound, and the unsaturated, non-sulfur silane coupling agent (d) has the formula (R1Lm)nSi(OR2)4?n,
where n is an integer selected from 0 or 1,
R1 is selected from
(iv) aryl having 6-14 carbon atoms and
(v) aralkyl having 6-14 carbon atoms;
L is a divalent hydrocarbyl having 1-5 carbon atoms where m is 1, and
R2 is selected from hydrocarbyl having 1-6 carbon atoms.
US Pat. No. 11,031,587

NEGATIVE ELECTRODE MATERIAL FOR LITHIUM-ION BATTERIES INCLUDING NON-FLAKY ARTIFICIAL GRAPHITE INCLUDING SILICON-CONTAINING PARTICLES, ARTIFICIAL GRAPHITE PARTICLES AND CARBONACEOUS MATERIAL

SHOWA DENKO K. K., Tokyo...

1. A negative electrode material for a lithium ion battery, comprising silicon-containing particles, artificial graphite particles and a carbonaceous material, the negative electrode material having an average interplanar spacing d002 of plane (002) by X-ray diffraction method of 0.3358 nm or less and a BET specific surface area of 5.7 m2/g or more and 6.1 m2/g or less, wherein at least part of the silicon-containing particles, the artificial graphite particles and the carbonaceous material form composite particles;wherein the silicon-containing particles are silicon particles having a SiOx (0 wherein the artificial graphite particles have a 50% particle diameter in a volume-based cumulative particle size distribution, D50, of 6.4 ?m or more and 12.2 ?m or less; a ratio between a peak intensity I110 of (110) plane and a peak intensity I004 of (004) plane of a graphite crystal determined by a powder XRD measurement, I110/I004, of or 0.11 or more and or 0.28 or less; and an average circularity of 0.88 or more and 0.89 or less.
US Pat. No. 11,026,977

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of ALYHQSPLL (SEQ ID NO: 45),wherein said cancer is selected from head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, and ovarian cancer.
US Pat. No. 11,028,257

FLAME-RETARDANT RESIN COMPOSITION, AND INSULATING WIRE, METAL CABLE, OPTICAL FIBER CABLE AND MOLDED ARTICLE USING THE SAME

Fujikura Ltd., Tokyo (JP...

1. A flame-retardant resin composition, comprising:a base resin composed of polyethylene and an acid-modified polyolefin;
a silicone compound;
a fatty acid-containing compound; and
a hindered amine-based compound including a hindered amine structure;
wherein the polyethylene includes a high-density polyethylene, a medium-density polyethylene and a low-density polyethylene,
wherein the high-density polyethylene has a density of 945 kg/m3 or more,
the medium-density polyethylene has a density of 914 kg/m3 or more and less than 945 kg/m3, and
the low-density polyethylene has a density of 864 kg/m3 or more and less than 914 kg/m3,
wherein the base resin contains the high-density polyethylene in an amount of 40 mass % or more and 60 mass % or less,
the base resin contains the medium-density polyethylene in an amount of 1 mass % or more and 35 mass % or less,
the base resin contains the low-density polyethylene in an amount of 10 mass % or more and 30 mass % or less, and
the base resin contains the acid-modified polyethylene in an amount of 1 mass % or more and 20 mass % or less,
wherein the silicone compound is blended in an amount of 3 parts by mass or more and 10 parts by mass or less relative to 100 parts by mass of the base resin,
the fatty acid-containing compound is blended in an amount of 3 parts by mass or more and 10 parts by mass or less relative to 100 parts by mass of the base resin,
the hindered amine-based compound is blended in an amount of 0.2 part by mass or more and 2.4 parts by mass or less relative to 100 parts by mass of the base resin, and
wherein the hindered amine-based compound is composed of a first hindered amine-based compound and a second hindered amine-based compound different from the first hindered amine-based compound.
US Pat. No. 11,026,978

COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS

Finch Therapeutics Holdin...

1. A method for treating relapsing-remitting multiple sclerosis in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutically active dose of a therapeutic composition comprising a community of fecal bacteria derived from a stool or portion thereof of a healthy human donor, wherein the therapeutic composition further comprises a cultured bacterial isolate.
US Pat. No. 11,026,979

HUMAN HEPATOCYTES AND USES THEREOF

ACCELERATED BIOSCIENCES C...

1. An isolated human hepatocyte, wherein the isolated human hepatocyte endogenously expresses transforming growth factor beta 1 (TGF?1), fibronectin, and collagen IV.
US Pat. No. 11,029,539

POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME

1. An ophthalmic device comprising a silicone-containing polymer and at least one water soluble, cross-linked copolymer comprising a plurality of primary polymer chains each having a degree of polymerization in the range of about 10 to about 10,000, wherein said copolymer is associated with at least one surface of said ophthalmic device and provides said ophthalmic device with a reduction in lipid uptake compared to the silicone-containing polymer of at least about 20%, and wherein said copolymer is free from terminal silicone segments.
US Pat. No. 11,026,980

FLOWABLE BIRTH TISSUE COMPOSITION AND RELATED METHODS

Triad Life Sciences, Inc....

1. A flowable porcine birth tissue composition comprisingdetergent-treated, milled porcine placental tissue; and
at least one carrier,
wherein the placental tissue is mixed with the at least one carrier to form the flowable porcine birth tissue composition, and
wherein the detergent includes at least one anionic detergent and at least one protease enzyme.
US Pat. No. 11,028,260

RUBBER COMPOSITION, RUBBER MOLDED BODY, AND METHOD FOR PRODUCTION OF RUBBER MOLDED BODY

SUMITOMO CHEMICAL COMPANY...

1. A rubber composition comprising:(A) an ethylene-?-olefin-based copolymer rubber comprising an ethylene unit and an ?-olefin unit having 3 or more carbon atoms;
(B) a fire retardant comprising a phosphate salt formed from phosphoric acid or a polyphosphoric acid and alkylene polyamine or polyalkylene polyamine;
(C) a thermally expandable graphite; and
(D) additive particles that are porous particles or particles having ion exchangeability, wherein the additive particles are silica particles, hydrotalcite particles, or a combination thereof, and wherein
a content of the fire retardant is 50 to 250 parts by mass and a content of the additive particles is 0.5 parts by mass to 10 parts by mass with respect to 100 parts by mass of the ethylene-?-olefin-based copolymer rubber.
US Pat. No. 11,026,982

METHOD FOR REDUCING THE LIKELIHOOD OF DEVELOPING BLADDER OR COLORECTAL CANCER IN AN INDIVIDUAL HUMAN BEING

1. A method for treating an individual suffering from one of bladder cancer and colorectal cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa and Klebsiella bacteria, andadministering to the individual an immune checkpoint inhibitor selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
US Pat. No. 11,028,262

RESIN COMPOSITION, ANISOTROPIC CONDUCTIVE FILM INCLUDING THE SAME, AND ELECTRONIC DEVICE

PANASONIC INTELLECTUAL PR...

1. A resin composition comprising:conductive particles;
a resin component; and
a curing agent,
wherein the conductive particles consist of solder,
the solder contains at least one selected from the group consisting of a tin-bismuth alloy, a tin-bismuth-indium alloy and a bismuth-indium alloy,
the resin component contains an epoxy resin and a phenoxy resin,
the curing agent contains a first compound having at least one thiol group and a second compound having an amino group,
a total amount of the epoxy resin and the phenoxy resin in the resin component is 90 mass % or more,
an amount of the phenoxy resin is 30 parts by mass to 50 parts by mass relative to 100 parts by mass of the epoxy resin,
an amount of the first compound is 35 parts by mass to 70 parts by mass relative to 100 parts by mass of the epoxy resin,
an amount of the second compound is 3 parts by mass to 20 parts by mass relative to 100 parts by mass of the epoxy resin, and
an amount of the conductive particles is 3 mass % to 30 mass % relative to a total mass of the resin composition being taken as 100 mass %.
US Pat. No. 11,026,983

BIFIDOBACTERIUM BREVE CBT BR3 STRAIN FOR PROMOTION OF GROWTH AND NUTRACEUTICAL COMPOSITION FOR PROMOTION OF GROWTH CONTAINING THE SAME

Cell Biotech Co., Ltd., ...

1. A method for alleviating one or more conditions selected from the group consisting of growth retardation, development retardation, and low body weight in a subject selected from the group consisting of human neonates, infants, and growing children, comprising:administering to the subject a nutraceutical composition that comprises:
an effective amount of Bifidobacterium breve CBT BR3 strain deposited under accession number KCTC 12201BP; and
an excipient or a carrier,
wherein said bacteria strain is lyophilized.
US Pat. No. 11,028,007

AUTOMOTIVE GLASS COMPOSITIONS, ARTICLES AND HYBRID LAMINATES

CORNING INCORPORATED, Co...

1. A glass article comprising a glass composition, the glass composition comprising:SiO2 in an amount in a range from 63 mol % to 75 mol %;
Al2O3 in an amount in a range from 7 mol % to 13 mol %;
R2O in an amount from 13 mol % to 24 mol %, wherein R2O=Li2O+Na2O+K2O;
P2O5 in an amount in a range from 0 mol % to 3 mol %;
Fe2O3 in an amount in a range from 0.01 mol % to 1 mol %;
wherein the glass composition comprises one or both of MgO and ZnO, wherein an amount of MgO is in a range from 0 mol % to 7 mol % and wherein an amount of ZnO is in a range from 0 mol % to 7 mol %,
wherein the glass composition is substantially free of Li2O,
wherein the glass composition is substantially free of B2O3,
wherein the glass article comprises a softening point in a range from 725° C. to 810° C.; and
wherein the glass article comprises an anneal point (° C.) and a softening point (° C.), and the relationship of (anneal point+softening point)/2 is in a range from 625° C. to 725° C.
US Pat. No. 11,028,263

POLYOXYMETHYLENE RESIN COMPOSITION

KOREA ENGINEERING PLASTIC...

1. A polyoxymethylene resin composition comprising:a polyoxymethylene homopolymer, a polyhydric alcohol containing three or more hydroxy groups in a molecule in an amount of 0.001 to 1 part by weight based on 100 parts by weight of the polyoxymethylene homopolymer;
a calcium phosphate compound in an amount of 0.01 to 1 part by weight based on 100 parts by weight of the polyoxymethylene homopolymer; and
an ethylene urea in an amount of 0.001 to 1 part by weight based on 100 parts by weight of the polyoxymethylene homopolymer;
wherein the polyoxymethylene homopolymer is obtained by polymerizing formaldehyde or trioxane in the presence of a polymerization catalyst and then adding a melamine-based polymerization terminator,
wherein the polyoxymethylene resin composition has a weight-reduction rate of 9% or less and a CH2O generation amount of 100 ppm or less.
US Pat. No. 11,026,984

USE OF ISOTHIOCYANATE DERIVATIVES AS MODULATORS OF PERIPHERAL AND NEUROPATHIC PAIN

Indena S.P.A., Milan (IT...

1. Method of treating oxaliplatin-induced neuropathy in a subject in need thereof, said method comprisingadministering glucomoringin, or glucomoringin des-thioglucoside, or an extract of Moringa oleifera seeds containing glucomoringin and/or glucomoringin des-thioglucoside to said subject; and
treating said subject of said oxaliplatin-induced neuropathy.
US Pat. No. 11,031,595

POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, METHOD OF PREPARING THE SAME, AND POSITIVE ELECTRODE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY WHICH INCLUDE THE POSITIVE ELECTRODE ACTIVE MATERIAL

LG Chem, Ltd.

1. A positive electrode active material comprising a lithium cobalt oxide doped with a doping element comprising a metallic element and a halide element,wherein the positive electrode active material is represented by Formula 1 and satisfies Equation 1:
Li(Co1-x-y-zM1xM2yM3z)O2-aHa  [Formula 1]
(2x+3y+4z?a)/(x+y+z+a)<2.5  [Equation 1]
wherein, in Formula 1,
M1 comprises at least one metallic element with an oxidation number of 2 selected from the group consisting of magnesium (Mg), calcium (Ca), iron (Fe), nickel (Ni), cobalt (Co), copper (Cu), zirconium (Zr), strontium (Sr), cadmium (Cd), and barium (Ba),
M2 comprises at least one metallic element with an oxidation number of 3 selected from the group consisting of aluminum (Al), scandium (Sc), yttrium (Y), niobium (Nb), indium (In), antimony (Sb), tantalum (Ta), iridium (Ir), and lanthanum (La),
M3 comprises at least one metallic element with an oxidation number of 4 selected from the group consisting of manganese (Mn), titanium (Ti), tin (Sn), germanium (Ge), molybdenum (Mo), technetium (Tc), hafnium (Hf), tungsten (W), and lead (Pb),
H comprises at least one halogen element selected from the group consisting of F?, Cl?, Br?, I?, and At?,
0?x?0.1, 0?y?0.1, 0?z?0.1, 0?x+y+z?0.1, and 0 wherein, in Equation 1,
x is an amount of moles of the metallic element with an oxidation number of 2, y is an amount of moles of the metallic element with an oxidation number of 3, z is an amount of moles of the metallic element with an oxidation number of 4, and a is an amount of moles of the halide element,
wherein the positive electrode active material has a particle size distribution whereby (D95?D5)/D50 of 1.5 to 2.0.
US Pat. No. 11,026,985

METHODS FOR REMOVING CONTAMINANTS FROM PLANT-DERIVED PHARMACEUTICALS

Sorbent Technologies, Inc...

1. A method of removing contaminants from a Cannabis plant-derived pharmaceutical, said method comprising:reacting one or more contaminants within a Cannabis plant-derived extract with an alkali metal hydroxide in a polar solvent to form one or more contaminant by-products in a reaction mixture, wherein said reacting step comprises:
adding the Cannabis plant-derived extract to the alkali metal hydroxide in the polar solvent to form the reaction mixture;
agitating the reaction mixture with mixing; and
adding a neutralizing acid to the reaction mixture, wherein the neutralizing acid comprises glacial acetic acid, or a dilute mineral acid comprising hydrochloric acid, sulfuric acid, or nitric acid; and
separating the one or more contaminant by-products from the Cannabis plant-derived extract so as to obtain a contaminant-reduced Cannabis plant-derived extract, wherein said separating step comprises:
adding a first alkane to the reaction mixture so as to form a non-aqueous liquid phase within the reaction mixture, wherein the first alkane comprises butane, pentane, cyclopentane, hexane, cyclohexane, heptane, octane, isooctane, or any combination thereof; and
separating an upper non-aqueous liquid phase from a lower aqueous liquid phase, the upper non-aqueous liquid phase comprising the first alkane and the contaminant-reduced Cannabis plant-derived extract,
wherein the contaminant-reduced Cannabis plant-derived extract comprises one or more cannabinoids.
US Pat. No. 11,028,265

ELECTRICALLY CONDUCTING POLY(PYRAZOLES)

The Government of the Uni...

1. A method of making a poly(3-amino-4-nitropyrazole) comprising the steps of:adding water to a flask;
adding potassium hydroxide to the water in the flask;
stirring the potassium hydroxide and the water in the flask;
dissolving the potassium hydroxide in the water in the flask and making a first solution;
adding 4-nitro 3-aminopyrazole to the first solution;
heating the 4-nitro 3-aminopyrazole in the first solution;
dissolving the 4-nitro 3-aminopyrazole in the first solution and forming a second solution;
adding sodium or potassium persulfate to the second solution; and
forming an electrically conducting poly(pyrazole);
wherein the electrically conducting poly(pyrazole) comprises poly(3-amino-4-nitropyrazole).
US Pat. No. 11,026,986

BEETROOT-CONTAINING COMPOSITION

Mission Salt, Inc., San ...

1. An enhanced food composition, comprising:a food having a salt content, wherein the food is selected from the group consisting of a sauce, a soup, and a condiment; and
a nitrate-containing vegetable effectively mixed with the salt content of the food;
wherein the ratio of nitrate-containing vegetable to salt content in the food is 1:16 to 1:4 based on the dry weight of the nitrate-containing vegetable and the salt content; and
wherein the nitrate-containing vegetable is selected from the group consisting of beetroot, arugula, spinach, lettuce, radish, Chinese cabbage or combinations thereof.
US Pat. No. 11,028,266

CURABLE ORGANOPOLYSILOXANE COMPOSITION, ENCAPSULANT AND SEMICONDUCTOR DEVICE

WACKER CHEMIE AG, Munich...

1. A curable organopolysiloxane composition, consisting of:(A) a branched organopolysiloxane having at least one silicon-bonded alkenyl group and at least one silicon-bonded aryl group per molecule, and having siloxane units of the formula: RSiO3/2 where R is a substituted or unsubstituted monovalent hydrocarbon group;
(B) a linear organopolysiloxane with both terminal ends of the linear organopolysiloxane bearing silicon-bonded hydrogen atoms and having at least one silicon-bonded aryl group per molecule;
(C) a hydrosilylation catalyst; and,
(D) at least 1 parts by weight, relative to 100 parts by weight of the total of components (A) and (B), of a low molecular weight siloxane selected from the group consisting of DVi4, MVi4Q, MVi6Q2, MVi3T, and mixtures thereof, and
optionally, a crosslinking agent, a phosphor, an inorganic or organic filler, a heat stabilizer, a dye, a pigment, a flame retardant, or a solvent, or a mixture of one or more of these optional ingredients,
wherein the curable organopolysiloxane composition does not comprise a linear organopolysiloxane having at least two silicon-bonded alkenyl groups and at least one silicon-bonded aryl group per molecule,
wherein the weight ratio of component (A) to component (B) is 70:30 to 90:10.
US Pat. No. 11,031,598

BINDER FOR POSITIVE ELECTRODE OF LITHIUM-SULFUR SECONDARY BATTERY AND METHOD FOR PREPARING POSITIVE ELECTRODE USING SAME

LG CHEM, LTD., Seoul (KR...

1. A binder for a positive electrode of a lithium-sulfur secondary battery, comprising:an acrylic polymer, wherein the acrylic polymer comprises
an acrylic monomer polymerized unit,
a non-acrylic monomer polymerized unit, and
a redox monomer polymerized unit,
wherein the acrylic polymer comprises the acrylic monomer polymerized unit in an amount of 30 wt. % or more based upon a total weight of the acrylic polymer.
US Pat. No. 11,026,988

TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF

INFINITUS (CHINA) COMPANY...

1. A method of inhibiting the growth of tumor, increasing the percentage of CD4+ and CD8+ cells in lymphocytes of tumor stroma, decreasing VEGF and TGF-?1 positive cells in tumor tissue, enhancing immunity, preventing and/or assisting in treating tumor, and/or restoring normal immune function, comprising administrating an effective amount of a traditional Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition consists of Lycii fructus polysaccharide, Polygonati rhizoma polysaccharide, Caryophylli flos oil and Cinnamomi cortex oil; andthe weight ratio of Lycii fructus polysaccharide, Polygonati rhizoma polysaccharide, Caryophylli flos oil and Cinnamomi cortex oil is (1 to 5):(1 to 5):(1 to 5):(1 to 5).
US Pat. No. 11,028,268

PROCESS FOR PRODUCING COMPOSITIONS CROSSLINKABLE TO ELASTOMERS

WACKER CHEMIE AG, Munich...

1. A process for producing moisture curable compositions crosslinkable to elastomers, comprising:in a first step, providing a mixture comprising
(1) at least one organopolysiloxane having at least two hydroxyl groups,
(2) at least one alkoxysilane of the formula
RSi(OR1)3  (I),and/or partial hydrolysates thereof,where R is a monovalent hydrocarbyl radical having 1 to 18 carbon atoms, andR1 is identical or different and is a monovalent hydrocarbyl radical having 1 to 8 carbon atoms, and(3) organosilicon compounds having at least one radical containing basic nitrogen and bonded via carbon to silicon,in a second step, adding to the mixture of the first step(4) at least one ketoximosilane of the formula
R2Si(ON?CR32)3  (II)and/or their partial hydrolysates,where R2 is a monovalent hydrocarbyl radical having 1 to 18 carbon atoms, andR3 is identical or different and is a monovalent hydrocarbyl radical having 1 to 5 carbon atoms, in amounts of at most 1 wt %, based on the total weight of the composition,and optionally adding further alkoxysilanes (2) and/or their partial hydrolysates and optionally further organosilicon compounds (3) in the second step or optionally in a third step subsequent to the second step, and adding and mixing(5) condensation catalysts,optionally(6) fillers,optionally(7) adhesion promoters,optionally(8) plasticizers,optionally(9) stabilizers, andoptionally(10) additives different from components (1)-(9), wherein in the third step, further alkoxysilanes (2) of the formula (I) and/or their partial hydrolysates and further organosilicon compounds (3) are added to the reaction mixture from the second step.
US Pat. No. 11,026,989

COMPOSITION FOR TREATING ERECTILE DYSFUNCTION BY ORCHIS ANATOLICA EXTRACT

JORDAN UNIVERSITY OF SCIE...

1. A formulation for treating erectile dysfunction in a male mammal comprising an effective amount of an Orchis anatolica root bulb extract, wherein the Orchis anatolica root bulb extract was extracted with 70% ethanol as an extraction solvent, and wherein the formulation is in the form selected from the group consisting of tablets, coated tablets, capsules, pills, suppositories, and/or ampoules.
US Pat. No. 11,027,501

HIGH LAP SHEAR STRENGTH, LOW BACK FACE SIGNATURE UD COMPOSITE AND THE PROCESS OF MAKING

HONEYWELL INTERNATIONAL I...

1. A polymeric fiber having a surface, said surface having a surface area, wherein said fiber surface is partially covered by a fiber surface finish, wherein said fiber surface finish covers from about 1.0% to 50.0% of the fiber surface area, and wherein said fiber has a tenacity of about 7 g/denier or more.
US Pat. No. 11,026,990

PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION

Shenzhen International In...

1. A method for treatment of infection of a virus in a subject, comprising administering to the subject a therapeutically effective amount of a PUM1 inhibitor, wherein the PUM1 inhibitor is an antisense oligomer that targets a nucleic acid molecule encoding PUM1 to block the synthesis of PUM1 wherein the virus is Hepres Simplex Virus type 1 or type 2.